A
Alcista
Alcista · 25%BPMC
$182.36
Precio del escenario
$129.460
+0.181 (+0.14%)Al cierre
Loading chart…
- Máximo
- 129.550
- Apertura
- 129.350
- Precio medio ponderado por volumen
- 129.44
- Volumen
- 2.98M
- Capitalización
- 6.80B
- Mínimo
- 129.300
- Importe
- 385.85M
- EV/EBITDA, TTM
- -568.81
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Recomendaciones de analistas (9)
+0.97% de potencial alcista
Comprar
9 Comprar
0 Mantener
0 Vender
Actual: 129.46
Mínimo
129.00
Promedio
130.71
Máximo
135.00
Wells Fargo
Equal Weight
$129
2025-06-18
Wells Fargo
2025-06-18
Precio objetivo
$129
Equal Weight
Morgan Stanley
Equal Weight
$129
2025-06-05
Morgan Stanley
2025-06-05
Precio objetivo
$129
Equal Weight
UBS
Neutral
$129
2025-06-05
UBS
2025-06-05
Precio objetivo
$129
Neutral
Citi
Neutral
$129
2025-06-04
Citi
2025-06-04
Precio objetivo
$129
Neutral
Citizens JMP
Market Perform
—
2025-06-03
Citizens JMP
2025-06-03
Precio objetivo
—
Market Perform
Métricas de valoración
El PER previsto actual de Blueprint Medicines Corp (BPMC) es -110.58, frente a su media de 5 años de -29.69.
Escenarios de precio de Alphio AI para BPMC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.507-22BenzingaSanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
3.007-20NASDAQ.COMBPMC Quantitative Stock Analysis
4.507-17NASDAQ.COMAfter Hours Most Active for Jul 16, 2025 : SRPT, NVDA, AAPL, BPMC, PFE, QQQ, INTC, CNH, GE, NI, WFC, F
8.507-14Globenewswire$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
9.007-08BenzingaCogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
Preguntas frecuentes sobre BPMC, respondidas por Alphio AI
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
9 analysts cover BPMC: 9 rate it Buy, 0 Hold and 0 Sell. The average price target is 130.71.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.